Date: 05/11/2026

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051.

NSE Symbol – NIDAN

Dear Sir/Madam,

Subject : Outcome of the Board Meeting held today i.e. on 05th November 2026.

Time of commencement of Board Meeting : 12:30 P.M.
Time of conclusion of Board Meeting : 3:20 P.M.

This is to inform you that pursuant to Regulation 30 & Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and other applicable provisions, the Board of Directors of the Company at its meeting held today have:

1. Approved the Unaudited Financial Results of the Company for the half year ended 30th September, 2026;
2. Taken on record the Limited Review Report by the Statutory Auditors of the Company for the aforesaid results**;**

In view of the above, we hereby enclose the following:

1. Unaudited Financial Results of the Company for the half year ended 30th September, 2026.
2. Limited Review Report on unaudited Financial Results of the Company for the half year ended 30th September, 2026.

The extract of Unaudited Financial Results shall be published in the newspapers in the format prescribed under Regulation 47 of the (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting of the Board of Directors of the Company commenced at 12:30 PM and concluded at 3:20 PM.

This is for your information and records.

Thanking you,

Yours sincerely,
For Nidan Laboratories and Healthcare Limited

TEJAL ANIL JAYAKAR
Digitally signed by TEJAL ANIL JAYAKAR
Date: 2026.11.05 15:30:32 +05'30'

Tejal Anil Jayakar
Executive Director & CFO
(DIN: 07984686)

Nidan Laboratories And Healthcare Limited

CIN - L33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment, Vartak Road, Virar (W), 401303

Tel No. +91 8975610000, E-Mail:cs@nidanhealthcare.co.in, Website: www.nidanhealthcare.co.in

Statement of UnAudited Financial Results for the Half Year Ended as on 30th September 2026

Rs in lakhs

	Particulars	Half Year Ended			Year Ended
		30-Sep-26	30-Sep-25	31-Mar-26	31-Mar-26
		Unaudited	Unaudited	Audited	Audited
1	**Income**				
	a) Revenue from Operations	1,201.76	1,312.10	1,242.06	2,554.16
	b) Other Income	146.61	116.96	68.61	185.57
	Total Income (a+b)	**1,348.37**	**1,429.06**	**1,310.67**	**2,739.73**
2	**Expenses**				
	a) Cost of Materials Consumed	54.55	40.35	57.92	98.27
	b)Changes in inventories of Finished Goods, Work in Progress and Stock- in- Trade	1.53	1.26	0.46	1.72
	c) Employee benefit expenses	204.76	211.77	218.46	430.23
	d) Finance Costs	102.07	88.48	107.16	195.64
	e) Depreciation and Amortization expenses	94.89	92.26	97.52	189.78
	f) Other Expenses	743.75	804.61	735.10	1,539.71
	Total Expenses (a to f)	**1,201.54**	**1,238.74**	**1,216.62**	**2,455.35**
3	**Profit before Exceptional and Extraordinary Items & Tax**	**146.81**	**190.32**	**94.05**	**284.38**
4	**Exceptioinal & Extraordinary Items**	-	-	**40.00**	40.00
5	**Profit before Tax and after exceptional & extraordinary item (3-4)**	**146.81**	**190.32**	**54.05**	**244.38**
6	**Tax Expenses**				
	a) Current Tax	20.50	43.50	21.50	65.00
	b) Deferred Tax Asset/Liability	17.03	3.45	9.92	13.37
	c) Tax of earlier year	-	-	15.41	15.41
	Total tax expenses	**37.53**	**46.95**	**46.82**	**93.77**
7	**Profit for the period / year**	**109.29**	**143.37**	**7.22**	**150.60**
8	Paid-up equity share capital (Face value of Rs 10/- per share)	1,390	1,390	1,390	1,390
	Earnings Per Share (not annualized for the half year ended)				
	a) Basic EPS	0.79	1.03	0.05	1.08
9	b) Diluted EPS	0.79	1.03	0.05	1.08

Notes:

1)The above Financial Results are reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 5th November 2026.

2) The equity shares of the company are listed on SME Stock Exchange as referred in Chapter XB of SEBI (Issue of Capital and Disclosure requirements)Regulations,2009 and hence exempted from Compulsary adoption of Ind AS for the preparation of Financial statements vide Notification dated 16th February,2015 issued by ministry of corporate affairs.

3) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.

4) The figures of the corresponding previous half year have been regrouped/rearranged wherever considered necessary to make them comparable

For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar
Executive Director & CFO
DIN:07984686

Date : 5th November, 2026
Place : Mumbai

Nidan Laboratories And Heatlhcare Limited

Statement of Assets & Liabilities as at 30th September 2026

Rs in lakhs

	Particulars	As at 30th September 2026 (UnAudited)	As at 31st March 2026 (Audited)
I	**Equity & Liabilities**		
	1. Shareholders' funds		
	Equity Share Capital	1,390.00	1,390.00
	Reserves and Surplus	5,688.19	5,578.90
		7,078.19	**6,968.90**
	2. Non - Current Liabilities		
	(a) Long - Term Borrowings	314.31	363.50
	(b) Other Long term liabilities	4.75	6.39
	(c) Long Term Provisions	39.10	39.10
		358.16	**408.99**
	3. Current Liabilities		
	(a) Short - Term Borrowings	910.50	752.87
	(b) Trade Payables		
	(i) Total outstanding due of micro enterprises and small enterprises	1.83	8.20
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	64.90	69.19
	(c) Other Current Liabilities	141.53	136.02
	(d) Short - Term Provisions	75.80	55.36
		1,194.56	**1,021.62**
	TOTAL	**8,630.91**	**8,399.52**
II	**Assets**		
	1. Non - Current Assets		
	(a) Property Plant & Equipment and Intangible Assets		
	(i) Property, Plant & Equipments	1,444.01	1,489.69
	(ii) Intangible Asset	1.45	1.45
	(ii) Capital workin progress	15.11	15.11
	(b) Non-Current Investments	2,000.00	2,000.00
	(c) Long - Term Loans and Advances	3,549.98	3,299.37
	(d) Deferred Tax Asset (Net)	46.47	63.50
	(e) Other Non Current Assets	74.51	74.25
		7,131.53	**6,943.38**
	2. Current Assets		
	(a) Inventories	51.46	52.99
	(b) Trade Receivables	208.65	221.68
	(c) Cash and Cash Equivalents	104.00	199.44
	(d) Short - Term Loans and Advances	772.40	636.36
	(e) Other Current Assets	362.87	345.66
		1,499.38	**1,456.14**
	TOTAL	**8,630.91**	**8,399.52**

For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar
Executive Director & CFO
DIN:07984686

Date : 5th November 2026
Place : Mumbai

Nidan Laboratories And Healthcare Limited

Statement Of Cash Flows for the half year ended 30th September 2026

Rs. in lakhs

Particulars	Half Year ended 30th September 2026	Year ended 31st March 2026
A - CASH FLOW FROM OPERATING ACTIVITIES		
Profit Before Tax	146.81	244.38
Add/ (less) Adjustment for:		
Interest Income	(82.20)	(182.57)
Interest Expenses	91.82	167.66
Interest on income tax	-	18.39
Sundry Balance written off	-	-
Sundry balance written back	(0.36)	(2.34)
Depreciation on property plant & equipment	94.89	189.78
(Gain)/loss on sale of property, plant and equipment	(63.68)	-
Operating Profit Before Working Capital Changes	**187.28**	**435.29**
Add/ (less): Adjustments for Changes in working capital:		
(Increase) / decrease in Trade Receivable	13.04	(94.90)
(Increase)/ decrease in Other Current Assets	(17.18)	(29.43)
(Increase) / decrease in Inventories	1.53	1.72
Increase / (decrease) in Trade payables	(10.31)	(16.54)
Increase / (decrease) in Other current Liability	5.51	(6.70)
Increase / (decrease) in Short Term Provision	-	(3.27)
Increase / (decrease) in Long term Provisions	-	(20.23)
Cash Generated from Operations	**179.86**	**265.95**
Add/ (less) : Direct taxes paid (net of refund received)	(0.07)	(99.22)
Net Cash Inflow / (outflow) from Operating Activities	**179.79**	**166.73**
B - CASH FLOW FROM INVESTING ACTIVITIES		
Acquisition of property, plant and equipment / intangible assets / Capital work in progress	(79.77)	(47.67)
Investment in group company	-	-
Proceeds from sale of property, plant and equipment	94.24	-
(Increase) / decrease in long term security deposit	(0.26)	(5.35)
(Increase) / Decrease in Long term loans and advances (net)	(222.02)	92.13
(Increase) / decrease in Short Term Loans and Advances	(136.04)	(203.82)
Interest received	53.61	170.83
Net cash inlow/(outflow) from Investing Activities	**(290.24)**	**6.10**
C - CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds / (repayment) of borrowings (net)	108.44	5.33
Increase / (decrease) in Long term security deposit liability	(1.64)	(1.00)
Interest Expenses	(91.82)	(167.66)
Net Cash inflow/(outflow) from Financing Activities	**14.99**	**(163.32)**
Net (Decrease) / Increase in Cash and Cash Equivalents (A+B+C)	(95.44)	9.49
Add: Cash and Cash Equivalents at the beginning of the year	199.44	189.95
Cash and Cash Equivalents at the end of the year	**104.00**	**199.44**

Cash and Cash Equivalents at the end of the year consists of cash in hand and Balances with Banks are as follows

Particulars	As at 30th September 2026	As at 31st March 2026
Cash on hand	102.07	81.26
Balances with Banks	1.93	118.18
Cash and Cash Equivalents	**104.00**	**199.44**

For and on behalf of the Board of Directors
Nidan Laboratories And Healthcare Limited

Tejal Anil Jayakar
Executive Director & CFO
DIN: 07984686

Date : 5th November 2026
Place : Mumbai

Nidan Laboratories And Healthcare Limited
CIN - L33111MH2000PLC129883
Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment,
Vartak Road, Virar (w), 401303
Tel No. +91 8975610000, E-Mail : cs@nidanhealthcare.co.in, Website : www.nidanhealthcare.co.in

Extract of Unaudited Financial Results for the Half Year Ended on 30th September, 2026

Rs in lakhs

S.No.	Particulars	Half Year Ended 30th September 2026	Half Year Ended 30th September 2025	Half Year Ended 31st March 2026	Year Ended 31st March 2026
		(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	Total Income from Operations	1,201.76	1,312.10	1,242.06	2,554.16
2	Net Profit for the period / year (before tax, exceptional and/or extraordinary items)	146.81	190.32	94.05	284.38
3	Net Profit for the period / year before tax (after exceptional and/or extraordinary items)	146.81	190.32	54.05	244.38
4	Net Profit for the period / year after tax (after exceptional and/or extraordinary items)	109.29	143.37	7.22	150.60
5	Total Comprehensive income for the period /year [comprising Profit for the period / year (after tax) and other comprehensive Income (after tax)]	109.29	143.37	7.22	150.60
6	Paid up Equity Share Capital	1,390.00	1,390.00	1,390.00	1,390.00
7	Reserves (exluding revaluation reserve)				5,578.90
8	Earnings Per Share (of Rs 10/-each) (not annualized for the half year ended)				
	Basic	0.79	1.03	0.05	1.08
	Diluted	0.79	1.03	0.05	1.08

Notes:-

1) The above is an extract of Unaudited Financial Results for Half Year Ended 30th September 2026 which have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at the meeting held on 5th November, 2026 and filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of the Financial Results are available on the Stock Exchange website: www.nseindia.com and Company's website : www.nidanhealthcare.co.in

2) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.

3) Figures of the previous period have been regrouped wherever necessary, to correspond with the figures of the current period.

For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar
Executive Director & CFO
DIN:07984686

Date : 5th November, 2026
Place : Mumbai

R. K. CHAPAWAT & CO.
CHARTERED ACCOUNTANTS

Limited Review Report on unaudited financial results of Nidan Laboratories & Healthcare Limited for the half year ended 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Nidan Laboratories & Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Nidan Laboratories & Healthcare Limited** ("the Company") for the Half Year ended 30th September 2026 being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 ("Listing Regulations").

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R.K Chapawat & Co.
Chartered Accountants
Firm's Registration No. 101708W

R. K. CHAPAWAT & CO. F.R.N. 101708 W Chartered Accountants

Kamlesh Chapawat
Partner
M. No. 181441
UDIN: - 26181441UCMCXM7562
Place: Mumbai
Date: 5th November 2026

Office : 122, Shripal Shopping Center, Near Petrol Pump, Agashi Road, Virar (West), Dist.-Palghar-401303.
9766095540 / 9769132203 ravindra_chapawat@rediffmail.com | info.chapawat@gmail.com